Tumor-penetrating peptides: a shift from magic bullets to magic guns
Related Experiment Video
Updated: Jun 12, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
1Université catholique de Louvain, Institute of Experimental and Clinical Research, Pole of Pharmacology and Therapeutics, Angiogenesis and Cancer Research Laboratory, Brussels, Belgium. olivier.feron@uclouvain.be
Abstract:
The targeted delivery of drugs and imaging agents to tumor vessels is an attractive strategy to enhance anticancer therapy and tumor detection, but such targeting does not mean efficient distribution into the tumor. Two consecutive papers, one in Cancer Cell and one in Science, report that a single peptide has the potential to selectively deliver a large variety of therapeutic agents and diagnostics to a tumor site and then to ensure their distribution deep in the tumor parenchyma. This peptide has the capacity to bind specific alpha(V) integrins through an arginine-glycine-aspartate motif and, after local proteolysis reveals a cryptic arginine/lysine-X-X-arginine/lysine motif, to bind the neuropilin-1 receptor and thereby increase tumor vascular permeability. Remarkably, this penetrating peptide works not only when it is conjugated to the payload, but also when it is coadministered with small molecules, nanoparticles, or monoclonal antibodies.
Insights
A novel peptide enhances drug delivery and distribution within tumors by targeting specific receptors. This breakthrough improves anticancer therapy and tumor imaging, working even when co-administered with various agents.
Area of Science:
- Oncology
- Molecular Biology
- Biotechnology
Background:
- Targeted drug delivery to tumors aims to improve cancer therapy and detection.
- Efficient drug distribution deep into tumor tissue remains a significant challenge.
Purpose of the Study:
- To identify and characterize a peptide capable of selective tumor targeting and deep tissue penetration.
- To evaluate the peptide's efficacy in delivering various therapeutic and diagnostic agents.
Main Methods:
- A peptide was designed to target alpha(V) integrins via an arginine-glycine-aspartate (RGD) motif.
- Upon local proteolysis, a secondary motif was exposed, binding to the neuropilin-1 receptor to increase vascular permeability.
- The peptide's delivery capabilities were tested when conjugated to payloads or co-administered with other agents.
Main Results:
- The peptide selectively binds to alpha(V) integrins at the tumor site.
- Post-proteolysis, it binds neuropilin-1, enhancing tumor vascular permeability and allowing deeper penetration.
- Effective delivery and distribution were achieved for various agents, including small molecules, nanoparticles, and antibodies.
Conclusions:
- A single peptide can effectively target tumors and facilitate deep drug penetration.
- This peptide represents a versatile platform for enhancing anticancer therapies and diagnostic imaging.
- Its efficacy is demonstrated both in conjugated form and through co-administration, offering flexible therapeutic strategies.
More Related Videos
10:33Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
Published on: April 25, 2025
09:01Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy
Published on: May 22, 2020
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...